Citius Pharmaceuticals: Bilanzvorlage zum letzten Quartal
Citius Pharmaceuticals hat am 14.02.2025 Zahlen zum jüngsten Quartal vorgelegt, das am 31.12.2024 endete.Der Verlust je Aktie belief sich auf 1,30 USD. Im Vorjahresquartal...
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Citius Pharmaceuticals hat am 14.02.2025 Zahlen zum jüngsten Quartal vorgelegt, das am 31.12.2024 endete.Der Verlust je Aktie belief sich auf 1,30 USD. Im Vorjahresquartal...
Nasdaq grants Citius Pharmaceuticals compliance extension
Citius Pharmaceuticals to receive $2.4 million in NJ funding